Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceuticals company AbbVie (ABBV 0.98%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at AbbVie and see what CAPS investors are saying about the stock right now.
AbbVie facts
|
Headquarters (founded) |
North Chicago, Ill. (2012) |
|
Market Cap |
$58.3 billion |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$18.0 billion |
|
Management |
Chairman/CEO Richard Gonzalez |
|
Trailing-12-Month Operating Margin |
43.8% |
|
Cash/Debt |
$4.6 billion / $0 |
|
Dividend Yield |
1.1% |
|
Competitors |
GlaxoSmithKline |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 108 members who have rated AbbVie believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, czheng393, offered a cautiously bullish take on AbbVie:
(ABT 0.49%)
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
